Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result

JAMA Surgery

Volumn 148, Issue 5, 2013, Pages 456-461

  Jones, Edward L ^a   Jones, Teresa S ^a   Pearlman, Nathan W ^a   Gao, Dexiang ^c   Stovall, Robert ^a   Gajdos, Csaba ^a   Kounalakis, Nicole ^a   Gonzalez, Rene ^b   Lewis, Karl D ^b   Robinson, William A ^b   McCarter, Martin D ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CUTANEOUS MELANOMA; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE DATABASE; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; SKINFOLD THICKNESS; TERTIARY HEALTH CARE; TUMOR LOCALIZATION; TUMOR RECURRENCE; UNIVERSITY HOSPITAL;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84874729764     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.1335     Document Type: Article

References (24)

1. Cancer facts and figures 2005. American Cancer Society website. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2005. Accessed April 27, 2012.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Kretschmer L, Starz H, Thoms KM, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129(6):1435-1442.
4. Scoggins CR, Ross MI, Reintgen DS, et al Sunbelt Melanoma Trial. Gender-related differences in outcome for melanoma patients. Ann Surg . 2006;243(5):693-698, discussion 698-700.
5. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: II, prognostic factors in patientswith stage I (localized) melanoma. Surgery. 1979;86(2):343-351.
6. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634. (Pubitemid 32786275)
7. McMasters KM, Noyes RD, Reintgen DS, et al Sunbelt Melanoma Trial. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86(4):212-223. (Pubitemid 38880288)
8. Kienstra MA, Padhya TA. Head and neck melanoma. Cancer Control. 2005;12(4):242-247. (Pubitemid 41552316)
9. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976-983. (Pubitemid 29109331)
10. Mays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2mmBreslow thickness undergo sentinel lymph node biopsy? Cancer. 2010;116(6):1535-1544.
11. Scoggins CR, Bowen AL, Martin RC II, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145(7):622-627.
12. Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg. 2008;248(3):378-386.
13. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or IImelanoma. J Clin Oncol. 1998;16(6):2253-2260. (Pubitemid 28265065)
14. Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17(3):709-717.
15. Carlson GW, Murray DR, Thourani V, Hestley A, Cohen C. The definition of the sentinel lymph node in melanoma based on radioactive counts. Ann Surg Oncol. 2002;9(9):929-933. (Pubitemid 35265647)
16. Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29(3):305-317. (Pubitemid 40321965)
17. Morton DL, Cochran AJ, Thompson JF, et al Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302-311, discussion 311-313.
18. Saltman BE, Ganly I, Patel SG, et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck. 2010;32(12):1686-1692.
19. Conway WC, Faries MB, Nicholl MB, et al. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16(6):1548-1552.
20. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233(2):250-258. (Pubitemid 32106080)
21. Chao C, Wong SL, Ross MI, et al Sunbelt Melanoma Trial Group. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. AmJ Surg. 2002;184(6):520-524, discussion 525.
22. Roach BA, Burton AL, Mays MP, et al. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg. 2010;200(6):759-763, discussion 763-764.
23. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011;104(4):379-385.
24. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452- 2459.